{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:18:40Z","timestamp":1771013920831,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1378\/chest.127.3.851","type":"journal-article","created":{"date-parts":[[2005,3,12]],"date-time":"2005-03-12T01:58:48Z","timestamp":1110592728000},"page":"851-860","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Airway and Systemic Effects of Hydrofluoroalkane Formulations of High-Dose Ciclesonide and Fluticasone in Moderate Persistent Asthma"],"prefix":"10.1016","volume":"127","author":[{"given":"Daniel K. C","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas C","family":"Fardon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline E","family":"Bates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay","family":"Haggart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley C","family":"McFarlane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J","family":"Lipworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1378\/chest.127.3.851_bib1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0091-6749(03)01859-1","article-title":"Inhaled corticosteroids: past lessons and future issues","volume":"112","author":"Allen","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1378\/chest.127.3.851_bib2","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1210\/jcem.87.5.8447","article-title":"Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide","volume":"87","author":"Weinbrenner","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1378\/chest.127.3.851_bib3","unstructured":"Kaliner M, White M, Chervinsky P, et al. Ciclesonide, a novel inhaled corticosteroid, does not suppress hypothalamic-pituitary-adrenal-axis function [abstract]. Allergy Clin Immunol Int 2003; 15(suppl):O17"},{"issue":"165(suppl)","key":"10.1378\/chest.127.3.851_bib4","article-title":"Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and PC20 for adenosine in asthma patients [abstract]","volume":"G84","author":"Pauwels","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.127.3.851_bib5","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/thx.52.5.476","article-title":"Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids","volume":"52","author":"Lipworth","year":"1997","journal-title":"Thorax"},{"key":"10.1378\/chest.127.3.851_bib6","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJM199201233260403","article-title":"The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone","volume":"326","author":"Schlaghecke","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.127.3.851_bib7","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1164\/ajrccm.159.4.9806052","article-title":"Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment: the AMPUL Study Group","volume":"159","author":"Sont","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.127.3.851_bib8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0002-9343(99)00435-0","article-title":"Dose-response evaluation of the therapeutic index for inhaled budesonide in patients with mild-to-moderate asthma","volume":"108","author":"Wilson","year":"2000","journal-title":"Am J Med"},{"key":"10.1378\/chest.127.3.851_bib9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1365-2125.2004.02108.x","article-title":"Effects of hydrofluoroalkane formulations of ciclesonide 400 \u03bcg once daily vs fluticasone 250 \u03bcg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma","volume":"58","author":"Lee","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1378\/chest.127.3.851_bib10","first-page":"S141","article-title":"Expert panel report: guidelines for the diagnosis and management of asthma; update on selected topics 2002","volume":"110","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1378\/chest.127.3.851_bib11","unstructured":"British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 2003; 58(suppl):i1\u2013i94"},{"key":"10.1378\/chest.127.3.851_bib12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1164\/ajrccm.161.1.ats11-99","article-title":"Guidelines for methacholine and exercise challenge testing-1999: this official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999","volume":"161","author":"Crapo","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.127.3.851_bib13","first-page":"1107","article-title":"American Thoracic Society","volume":"152","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.127.3.851_bib14","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1183\/09031936.97.10071683","article-title":"Exhaled and nasal nitric oxide measurements: recommendations; the European Respiratory Society Task Force","volume":"10","author":"Kharitonov","year":"1997","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.127.3.851_bib15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1034\/j.1399-3003.1999.14a08.x","article-title":"Development and validation of the Mini Asthma Quality of Life Questionnaire","volume":"14","author":"Juniper","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.127.3.851_bib16","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1378\/chest.116.4.931","article-title":"Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate","volume":"116","author":"Weiner","year":"1999","journal-title":"Chest"},{"key":"10.1378\/chest.127.3.851_bib17","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0140-6736(00)02581-2","article-title":"Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomized crossover study","volume":"356","author":"Brutsche","year":"2000","journal-title":"Lancet"},{"key":"10.1378\/chest.127.3.851_bib18","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1136\/thorax.58.3.258","article-title":"Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects","volume":"58","author":"Harrison","year":"2003","journal-title":"Thorax"},{"key":"10.1378\/chest.127.3.851_bib19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1081-1206(10)61497-4","article-title":"Effects of high-dose inhaled fluticasone propionate on the hypothalamic-pituitary-adrenal axis in asthmatic patients with severely impaired lung function","volume":"93","author":"Lee","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1378\/chest.127.3.851_bib20","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1378\/chest.112.5.1248","article-title":"Evaluation of corticotropin releasing factor stimulation and basal markers of hypothalamic-pituitary-adrenal axis suppression in asthmatic patients","volume":"112","author":"Clark","year":"1997","journal-title":"Chest"},{"key":"10.1378\/chest.127.3.851_bib21","doi-asserted-by":"crossref","unstructured":"Kunka R, Andrews S, Pimazzoni M, et al. From hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs. Respir Med 2000; 94(suppl):S10\u2013S16","DOI":"10.1016\/S0954-6111(00)80144-4"},{"key":"10.1378\/chest.127.3.851_bib22","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(99)03581-3","article-title":"Differences in lung bioavailability between different propellants for fluticasone propionate","volume":"354","author":"Wilson","year":"1999","journal-title":"Lancet"},{"key":"10.1378\/chest.127.3.851_bib23","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1378\/chest.122.2.618","article-title":"Therapeutic ratio of hydrofluoroalkane and chlorofluorocarbon formulations of fluticasone propionate","volume":"122","author":"Fowler","year":"2002","journal-title":"Chest"},{"key":"10.1378\/chest.127.3.851_bib24","doi-asserted-by":"crossref","unstructured":"Ayres JG, Millar AB, Sykes AP. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma: UK Study Group. Respir Med 2000; 94(suppl):S42\u2013S50","DOI":"10.1016\/S0954-6111(00)80149-3"},{"key":"10.1378\/chest.127.3.851_bib25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1046\/j.1365-2265.1999.00652.x","article-title":"Dose response with fluticasone propionate on adrenocortical activity and recovery of basal and stimulated responses after stopping treatment","volume":"50","author":"Wilson","year":"1999","journal-title":"Clin Endocrinol"},{"key":"10.1378\/chest.127.3.851_bib26","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1081-1206(10)62140-0","article-title":"Dose response of inhaled corticosteroids on bronchial hyperresponsiveness: a meta-analysis","volume":"90","author":"Currie","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1378\/chest.127.3.851_bib27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1067\/mai.2002.120559","article-title":"Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma","volume":"109","author":"Dempsey","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1378\/chest.127.3.851_bib28","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1136\/thorax.58.6.500","article-title":"Sustained reduction in bronchial hyperresponsiveness with inhaled fluticasone propionate within three days in mild asthma: time course after onset and cessation of treatment","volume":"58","author":"Sovijarvi","year":"2003","journal-title":"Thorax"},{"key":"10.1378\/chest.127.3.851_bib29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1046\/j.1365-2125.2003.01813.x","article-title":"A proof of concept study to evaluate putative benefits of montelukast in moderate persistent asthmatics","volume":"55","author":"Currie","year":"2003","journal-title":"Br J Clin Pharmacol"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215310941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215310941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T06:43:58Z","timestamp":1757918638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369215310941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0012369215310941"],"URL":"https:\/\/doi.org\/10.1378\/chest.127.3.851","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Airway and Systemic Effects of Hydrofluoroalkane Formulations of High-Dose Ciclesonide and Fluticasone in Moderate Persistent Asthma","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1378\/chest.127.3.851","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}